Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYU6P5)

Drug Name

GS-9857 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 89921642
CAS Number: CAS 1535212-07-7
TTD Drug ID: DMYU6P5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis C virus NS3 helicase (HCV NS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ombitasvir + paritaprevir + ritonavir	DML9TI0	Hepatitis C virus infection	1E51.1	Approved	[3]
GS-9451	DMF910Q	Chronic HCV-1 infection	1E51.1	Phase 2	[4]
BILN-2061	DM2J36F	Hepatitis virus infection	1E50-1E51	Phase 2	[5]
VBY-376	DMU263R	Hepatitis C virus infection	1E51.1	Phase 1	[6]
ACH-2684	DMW6X0O	Hepatitis C virus infection	1E51.1	Phase 1	[7]
BMS-605339	DMY7ZRA	Hepatitis C virus infection	1E51.1	Terminated	[8]
GNF-PF-3464	DMWAKHD	Discovery agent	N.A.	Investigative	[9]
AcAsp-D-Gla-Leu-Ile-Cha-Cys	DMT74F5	Discovery agent	N.A.	Investigative	[10]
Cbz-Ile-Leu-L-(difluoro)aminobutyric acid	DMI53WR	Discovery agent	N.A.	Investigative	[10]
AcGlu-Dif-Ile-Cha-Cys	DMK6HGI	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus NS3 helicase (HCV NS3)	TTWXB3E	POLG_HCV1	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02202980) Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Gilead.
3	HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
4	Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
5	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
6	Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
7	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8	Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
9	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
10	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
11	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.